Evaluation of the use of evidence-based angiotensin-converting enzyme inhibitor criteria for the treatment of congestive heart failure: Opportunities for pharmacists to improve patient outcomes

Journal of Clinical Pharmacy and Therapeutics

Volumn 26, Issue 5, 2001, Pages 351-361

  Cooke, C ^b   Simmons, W K T ^c   Sketris, I ^d   Pearson, Glen J ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^d DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Angiotensin converting enzyme inhibitors; Congestive heart failure; Drug utilization evaluation (DUE); Drug utilization review (DUR); Guidelines

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLYCERYL TRINITRATE; HYDRALAZINE;

ADULT; AGED; ARTICLE; COMMUNITY CARE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE COURSE; EVALUATION; FEMALE; HOSPITAL; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; PHARMACIST; RETROSPECTIVE STUDY; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DRUG EVALUATION; ENZYME INHIBITORS; EVIDENCE-BASED MEDICINE; FEMALE; GUIDELINES; HEART FAILURE, CONGESTIVE; HOSPITALIZATION; HUMANS; MALE; MEDICAL RECORDS; PHARMACISTS; PILOT PROJECTS; REGRESSION ANALYSIS; SEX FACTORS; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 0034777387     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.2001.00364.x     Document Type: Article

References (48)

1. The management of chronic heart failure
2. Management of heart failure II: Counselling, education and lifestyle modifications
3. Diagnosis and management of heart failure: Canadian Cardiovascular Society's Consensus Conference
4. Medication compliance: A healthcare problem
5. ASHP Guidelines on angiotensin-converting enzyme inhibitors in patients with left ventricular dysfunction
6. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study
7. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
8. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure
9. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction
10. Effects of early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II
11. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction
12. Effects of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure
13. GISSI 3: Effects of lis-inopril and transdermal glyceryl trinitrate singly and together on 6 week mortality and ventricular function after acute myocardial infarction
14. Effects of an angiotensin-con-verstingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
15. Heart failure. Evaluation and care of patients with left ventricular systolic dysfunction
16. Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association task force on practice guidelines
17. Heart Failure Society of America guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction - Pharmacological approaches
18. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure
19. Reasons for underuse of angiotensin-converting enzyme inhibitors in patients with heart failure and left ventricular dysfunction
20. Patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure in two community hospitals
21. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure
22. Effect of a multidisciplinary intervention on medication compliance in elderly patients with congestive heart failure
23. National patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure
24. Factors determining angiotensin-converting enzyme inhibitor underutilization in heart failure in a community setting
25. Differences between primary care physicians and cardiologists in management of congestive heart failure: Relation to practice guidelines
26. Is optimal angiotensin-converting enzyme inhibitor dosing neglected in elderly patients with heart failure?
27. Mortality risk and patterns of practice in 4606 acute care patients with congestive heart failure. The relative importance of age, sex, and medical therapy
28. Temporal trends in pharmacotherapy for congestive heart failure at an academic medical center: 1990-95
29. Compliance with and dosing of angiotensin-converting-enzyme inhibitors before and after hospitalization
30. Determinants of angiotensin-converting enzyme inhibitor prescription in severe heart failure with left ventricular systolic dysfunction: The EPICAL Study
31. Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry
32. Angiotensin-converting enzyme inhibitor compliance and dosing among patients with heart failure
33. Effect of heart failure program on cardiovascular drug utilization and dosage in patients with chronic heart failure
34. Relational database for drug-use review of Tennessee Medicaid claims
35. Compliance issues with ACE inhibitors
36. Angiotensin-converting-enzyme inhibitors and renal function
37. Reliability of drug utilization evaluation as an assessment of medication appropriateness
38. Angiotensin converting enzyme (ACE) inhibitors and renal function: A review of the current status
39. Lithium and angiotensin-converting-enzyme inhibitors: Evaluation of a potential interaction
40. Cardiovascular diseases
41. Optimizing disease management at a health care system level: The rationale and methods of the improving cardiovascular outcomes in Nova Scotia (ICONS) Study
42. Are national consensus conferences or locally developed practice guidelines effective? An example in 7797 patients with congestive heart failure
43. An interactive workshop - An effective means of integrating the Canadian Cardiovascular Society clinical practice guidelines on congestive heart failure into Canadian family physicians' practice
44. The pharmacoeconomics of ACE inhibitors in chronic heart failure